explore -WSS

explore

author：explore 2025-09-28 22:52:44 - browse：3264

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： White House finalizes ITC's import ban of latest Apple Watches

knowledge

hotspot

WSS

Federal weight loss drug coverage is 30 years out of date

Ahead of JPM, here's who's profiting most in health care

Hospitals look to new technology to keep health care workers safe

The FDA must approve intranasal treatments for anaphylaxis

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Feng Zhang, Grail founder join forces on new gene editing startup

hotspot

explore

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

A single drug, study failures leave Anavex with nothing but cash

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

GSK Flovent asthma inhalers replaced by authorized generics

United colonoscopy coverage change 'may cost lives,' doctors say

Morgan Health, with ambitious aims, wants you to know it’s still here

Medical records are filled with copy

UCB departs biotech trade group BIO

Novavax promises a turnaround & Lilly roils the obesity market

A single drug, study failures leave Anavex with nothing but cash

hotspot

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Gain of function research would be limited under House proposal

Ahead of JPM, here's who's profiting most in health care

FDA's Woodcock to retire early next year

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

GSK Flovent asthma inhalers replaced by authorized generics

knowledge

explore

hotspot

leisure time